Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A₁ antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

S. Mustafa Drug Metabolism and Pharmacokinetics,

P. Venkatesh Drug Metabolism and Pharmacokinetics,

K. Pasha Drug Metabolism and Pharmacokinetics,

R. Mullangi Drug Metabolism and Pharmacokinetics,

N. R. Srinivas Drug Development, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad, IndiaCorrespondence[email protected]

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

P. Ahlawat & N. R. Srinivas. (2008) Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data. Xenobiotica 38:11, pages 1377-1385.
Read now

Articles from other publishers (5)

Nadia O. Bamfo, Chelsea Hosey-Cojocari, Leslie Z. Benet & Connie M. Remsberg. (2021) Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans. Pharmaceutical Research 38:7, pages 1139-1156.
Crossref

Paleerath Peerapen & Visith Thongboonkerd. 2019. Caffeinated and Cocoa Based Beverages. Caffeinated and Cocoa Based Beverages 235 256 .

Poonam Giri, Prashant Delvadia, Vipul Joshi, Priyal Trivedi & Nuggehally R Srinivas. (2018) Opposite effects of acute kidney injury on pharmacokinetics of renally and hepatobiliary excreted drugs. International Journal of Pharmacokinetics 3:2, pages 81-90.
Crossref

Amal Al-Saraf, René Holm & Carsten Uhd Nielsen. (2016) Tween 20 increases intestinal transport of doxorubicin in vitro but not in vivo. International Journal of Pharmaceutics 498:1-2, pages 66-69.
Crossref

Shin-ichi Matsumoto, Kenji Yoshida, Naoki Ishiguro, Tomoji Maeda & Ikumi Tamai. (2007) Involvement of Rat and Human Organic Anion Transporter 3 in the Renal Tubular Secretion of Topotecan [( S )-9-Dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride] . Journal of Pharmacology and Experimental Therapeutics 322:3, pages 1246-1252.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A₁ antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

Articles from other publishers (5)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

Citations (6)

Read on this site (1)

Articles from other publishers (5)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A₁ antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?